Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123135 | 0.91 | NPC1 (0.32) | MC4RNPC1LMNATP53RAB9A | |
| SCHEMBL4115233 | 0.73 | NPC1 (0.34) | MC4RNPC1LMNATP53RAB9A | |
| SCHEMBL4119898 | 0.71 | ALDH1A1 (0.35) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL4128095 | 0.69 | HSD11B1 (0.33) | — | |
| SCHEMBL4124067 | 0.67 | NPC1 (0.34) | MC4RNPC1LMNATP53RAB9A | |
| SCHEMBL4124062 | 0.66 | NPC1 (0.39) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL4115236 | 0.62 | DRD4 (0.45) | — | |
| SCHEMBL4109152 | 0.60 | SMN1; SMN2 (0.42) | NPC1LMNATP53RAB9ASMN1; SMN2 | |
| SCHEMBL4124065 | 0.59 | HTT (0.46) | LMNATP53SMN1; SMN2 | |
| SCHEMBL4126882 | 0.59 | RXFP1 (0.36) | NPC1LMNATP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566378-B1 | ISOINDOLINE DERIVATIVE | MARUISHI PHARMA (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | MARUISHI PHARMACEUTICAL CO., LTD. | 2009-07-02 | — | — | US | disclosed |
| US-7521451-B2 | Isoindoline derivative | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | MARUISHI PHARMACEUTICAL CO., LTD | 2006-03-09 | — | — | US | disclosed |
| EP-1566378-A1 | ISOINDOLINE DERIVATIVE | Maruishi Pharmaceutical Co., Ltd. (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052392-A1 | e.g. 5,6-dimethyl-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione;intravenous, water-soluble compounds useful for manufacturing an anasthetic, sedative agents; side effect reduction | CYP3A5, OPRD1, CYP3A7 | MC4R 3571/4885NPC1 3638/4885LMNA 3570/4885 |
| US-20090170835-A1 | ISOINDOLINE DERIVATIVES | OPRD1, OPRK1, OPRL1 | MC4R 1604/4885NPC1 2942/4885LMNA 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.